JPH0137376B2 - - Google Patents
Info
- Publication number
- JPH0137376B2 JPH0137376B2 JP59043265A JP4326584A JPH0137376B2 JP H0137376 B2 JPH0137376 B2 JP H0137376B2 JP 59043265 A JP59043265 A JP 59043265A JP 4326584 A JP4326584 A JP 4326584A JP H0137376 B2 JPH0137376 B2 JP H0137376B2
- Authority
- JP
- Japan
- Prior art keywords
- acidic substance
- stabilizing
- item
- acid
- acidic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000002378 acidificating effect Effects 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 229940049964 oleate Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 16
- 239000008187 granular material Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000004040 coloring Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003464 sulfur compounds Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59043265A JPS60185727A (ja) | 1984-03-05 | 1984-03-05 | ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法 |
| EP85301164A EP0159777A1 (en) | 1984-03-05 | 1985-02-21 | Stabilized 4-carbamoyl-imidazolium-5-olate |
| CA000475351A CA1235065A (en) | 1984-03-05 | 1985-02-27 | Stabilized 4-carbamoyl-imidazolium-5-olate preparations |
| ES540907A ES8700936A1 (es) | 1984-03-05 | 1985-03-04 | Un metodo de producir una composicion farmaceutica estabili-zada |
| KR1019850001346A KR850006131A (ko) | 1984-03-05 | 1985-03-04 | 안정화된 제약 조성물 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59043265A JPS60185727A (ja) | 1984-03-05 | 1984-03-05 | ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60185727A JPS60185727A (ja) | 1985-09-21 |
| JPH0137376B2 true JPH0137376B2 (enExample) | 1989-08-07 |
Family
ID=12659008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59043265A Granted JPS60185727A (ja) | 1984-03-05 | 1984-03-05 | ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0159777A1 (enExample) |
| JP (1) | JPS60185727A (enExample) |
| KR (1) | KR850006131A (enExample) |
| CA (1) | CA1235065A (enExample) |
| ES (1) | ES8700936A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014112530A1 (ja) | 2013-01-15 | 2014-07-24 | 富士フイルム株式会社 | ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドを含有する錠剤 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950010150B1 (ko) * | 1986-01-14 | 1995-09-11 | 쥬우가이세이야꾸 가부시끼가이샤 | 니코란딜 함유 주사제의 안정화 방법 |
| JP5266010B2 (ja) * | 2007-09-14 | 2013-08-21 | 富士フイルム株式会社 | ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物 |
| JP5458777B2 (ja) | 2009-09-28 | 2014-04-02 | 株式会社ジェイテクト | ダブルカルダンジョイントのカップリングヨーク |
| JP2013082706A (ja) * | 2011-09-28 | 2013-05-09 | Fujifilm Corp | ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド水和物の結晶 |
| TWI594988B (zh) * | 2011-09-28 | 2017-08-11 | 富士軟片股份有限公司 | ５－羥基－１ｈ－咪唑－４－甲醯胺．３／４水合物及其結晶之製造方法 |
| RU2630682C2 (ru) | 2011-09-28 | 2017-09-12 | Фуджифилм Корпорэйшн | Кристалл 5-гидрокси-1н-имидазол-4-карбоксамид•3/4 гидрата, способ его получения и кристалл 5-гидрокси-1н-имидазол-4-карбоксамида гидрата |
| BR112014026250A2 (pt) * | 2013-01-15 | 2017-06-27 | Fujifilm Corp | preparação de produto sólido embalado contendo 5-hidroxi-1h-imidazola-4-carboxamida ou sal do mesmo, ou hidrato dos mesmos |
| RU2603137C1 (ru) * | 2013-01-15 | 2016-11-20 | Фуджифилм Корпорэйшн | Сульфат 5-гидрокси-1н-имидазол-4-карбоксамида |
| EP3686189B1 (en) * | 2017-10-27 | 2021-09-01 | FUJIFILM Corporation | Production method for 5-hydroxy-1h-imidazole-4-carboxamide-3/4hydrate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181731A (en) * | 1976-09-07 | 1980-01-01 | Sumitomo Chemical Company, Limited | Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole |
| DE3176849D1 (en) * | 1980-11-05 | 1988-09-29 | Sumitomo Chemical Co | Pharmaceutical composition comprising 4-carbamoyl-imidazolium-5-olate |
-
1984
- 1984-03-05 JP JP59043265A patent/JPS60185727A/ja active Granted
-
1985
- 1985-02-21 EP EP85301164A patent/EP0159777A1/en not_active Ceased
- 1985-02-27 CA CA000475351A patent/CA1235065A/en not_active Expired
- 1985-03-04 ES ES540907A patent/ES8700936A1/es not_active Expired
- 1985-03-04 KR KR1019850001346A patent/KR850006131A/ko not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014112530A1 (ja) | 2013-01-15 | 2014-07-24 | 富士フイルム株式会社 | ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドを含有する錠剤 |
| US9248102B2 (en) | 2013-01-15 | 2016-02-02 | Fujifilm Corporation | Tablet containing 5-hydroxy-1H-imidazole-4-carboxamide |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1235065A (en) | 1988-04-12 |
| KR850006131A (ko) | 1985-10-02 |
| ES540907A0 (es) | 1986-11-16 |
| JPS60185727A (ja) | 1985-09-21 |
| EP0159777A1 (en) | 1985-10-30 |
| ES8700936A1 (es) | 1986-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910002641B1 (ko) | 산불안정화합물의 내복용 제제 | |
| US4933443A (en) | Method for preparing crystalline hydrate of oral celphalosporin and its composition | |
| US5017380A (en) | Gelatin hard capsule containing crystalline hydrate of oral cephalosporin | |
| EP1004305B1 (en) | Stabilized compositions containing benzimidazole-type compounds | |
| JP4608031B2 (ja) | アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化 | |
| US4248856A (en) | Sustained release pharmaceutical compositions | |
| US20090232889A1 (en) | Crystalline salts of quinoline compounds and methods for preparing them | |
| JPH0137376B2 (enExample) | ||
| KR910002670B1 (ko) | 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 | |
| HU198385B (en) | Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses | |
| RU2259828C2 (ru) | Способы стабилизации соединений на основе бензимидазола | |
| JPH05294831A (ja) | 内服用新規医薬製剤 | |
| JP2001213770A (ja) | テプレノンの安定化組成物及び安定化方法 | |
| JP4745573B2 (ja) | 抗菌医薬組成物 | |
| KR20120003906A (ko) | 염기성 첨가제를 함유하는 매트릭스형 서방성 제제 | |
| JPH05503540A (ja) | 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 | |
| JPH04360833A (ja) | １，４−ジヒドロピリジン誘導体を含有する製剤 | |
| ES2234051T3 (es) | Composiciones farmaceuticas de cilansetron estabilizadas contra la racemizacion. | |
| JPH0776172B2 (ja) | マトリツクス錠 | |
| CA1272192A (en) | Metal complexes of bis-indole compounds and aqueous pharmaceutical compositions containing them | |
| KR20050052361A (ko) | 휘산방지형 고형제제 및 그의 제조방법 | |
| JPH0770506A (ja) | フイルムコーティング組成物およびそれを用いた固形製剤 | |
| JPH11335302A (ja) | 安定な医薬組成物 | |
| KR920008161B1 (ko) | 오메프라졸 경구용 약제의 제조방법 | |
| JPH0222225A (ja) | 胃酸分泌抑制剤含有固型製剤 |